Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459159 · ClinicalTrials.gov registry record · Phase 2
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
A Phase 2 study, sponsored by Telik.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT01459159 is a Phase 2 study that was terminated before completion, run by Telik. The registered enrollment target is 162 participants.
The verdict
NCT01459159, a Phase 2 study, was terminated before completion, sponsored by Telik.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
Interventions
- DRUG ezatiostat hydrochloride (Telintra®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01459159
The ClinicalTrials.gov registry entry for NCT01459159 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ezatiostat hydrochloride (Telintra®) is the first listed.
NCT01459159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01459159 about?
NCT01459159 is a clinical study titled "Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome". This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT01459159?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2011-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01459159?
The interventions under investigation include: ezatiostat hydrochloride (Telintra®) (DRUG).
Who is sponsoring clinical trial NCT01459159?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.